The first PMDA-approved METex14 companion diagnostic

The first PMDA-approved METex14 companion diagnostic

Archer®MET is the first PMDA-approved METex14 companion diagnostic for NSCLC

ArcherMET tests for MET exon 14 (METex14) skipping mutations in non-small cell lung cancer (NSCLC) to identify patients who may benefit from new PMDA-approved targeted therapies.

ArcherMET is now available for clinical use →

METex14 skipping: An important biomarker for therapy selection

A new targeted therapy was approved by the PMDA for NSCLC patients with METex14 alterations, which is why it’s important to know every patient’s status.

Prevalence of select NSCLC Oncogenic Alterations1-11

  • METex14 skipping mutations lead to oncogenic MET signaling, resulting in poor prognosis.12
  • Deregulation of the MET pathway via MET mutations plays an important role in acquired resistance to EGFR-TKIs.13
  • METex14 skipping is associated with poor response to standard NSCLC therapies.14-18

There is now a new PMDA-approved targeted therapy for NSCLC patients with METex14 skipping

With ArcherMET, you can test for METex14 skipping mutations in NSCLC patients using tissue and blood samples

As a test kit with a simple workflow for testing tissue and liquid biopsies, ArcherMET can be easily added to any NSCLC diagnostic workflow.

Expand your NSCLC testing workflow with ArcherMET

Reliable results you can trust

ArcherMET leverages proprietary Anchored Multiplex PCR (AMP™) technology that can efficiently and accurately detect METex14 skipping mutations by sequencing RNA from tissue and ctDNA from blood.

Sensitivity*

Specificity*

*At 3.0% allele frequency using 5 ng ctDNA and 0.3% allele frequency using 30 ng ctDNA and 10 ng RNA.

Minimal sample requirements that ensure patient access to testing

RNA

  • 2–5 unstained FFPE slides
  • Minimum 5 x 5 mm2 tissue at 10% tumor content
  • Nucleic acid content: >10 ng RNA
  • No need for macrodissection

ctDNA

  • 10 mL whole blood
  • Nucleic acid content: >5 ng ctDNA
  • No need for invasive tissue biopsy

Identify METex14-positive patients with ArcherMET so your NSCLC patients can receive effective therapy sooner

How to order

ArcherMET is available for order through LSI Medience. Learn more about ArcherMET, including where to order, by emailing us at the button below.

Learn more

ArcherMET is only available for companion diagnostic use in Japan

References:

  1. Salgia R. Mol Cancer Ther. 2017;16:555-565.
  2. Chakravarty D, Gao J, Phillips S, et al. JCO Precis Oncol. 2017. Accessed March 3, 2020.
  3. Farago AF, Taylor MS, Doebele RC, et al. JCO Precis Oncol. 2018;2018.
  4. AACR Project GENIE Consortium. Cancer Discov. 2017;7:818-831.
  5. Ross JS, Ali SM, Fasan O, et al. Oncologist. 2017;22:1444-1450.
  6. Gainor JF, Varghese AM, Ou SH, et al. Clin Cancer Res. 2013;19:4273-4281.
  7. Mazières J, Peters S, Lepage B, et al. J Clin Oncol. 2013;31:1997-2004.
  8. Lin Q, Zhang H, Ding H, et al. J Transl Med. 2019;17:1-10.
  9. Tissot C, Couraud S, Tanguy R, et al. Lung Cancer. 2016;91:23-28.
  10. Bergethon K, Shaw AT, Ou SH, et al. J Clin Oncol. 2012;30:863-870.
  11. Awad MM, Oxnard GR, Jackman DM, et al. J Clin Oncol. 2016;34:721-730.
  12. Awad MM, Leonardi GC, Kravets S, et al. Lung Cancer (suppl). 2019;133:96-102.
  13. Ariyawutyakorn W, Saichaemchan S, Varella-Garcia M. J Cancer. 2016;7(6):633-49.
  14. Dimou A, Leonardi GC, Kravets S, et al. PLoS One. 2014;9:e107677.
  15. Guo B, Cen H, Tan X, et al. PLoS One. 2014;9:e99399.
  16. Sabari JK, Leonardi GC, Shu CA, et al. Ann Oncol. 2018;29: 2085-2091.
  17. Baba K, Tanaka H, Sakamoto H, et al. Thorac Cancer. 2019;10:369-372.
  18. Reis H, Metzenmacher M, Goetz M, et al. Clin Lung Cancer. 2018;19:e441-e163.
ArcherDX Japan Contact (call for inquiries)
Jingumae Tower Building 14F, 1-5-8 Jingumae, Shibuya-ku Tokyo 150-0001
(03)6741-7159
[email protected]
Designated Marketing Approval Holder
Cobridge KK
KDX Kojimachi Building 5F, 3-3-4 Kojimachi, Chiyoda-ku Tokyo 102-0083
(03)5275-3570
[email protected]